Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319034 | 0.81 | GSK3B (0.53) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL1531268 | 0.81 | MAPT (0.63) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL166726 | 0.79 | MAPT (0.54) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL3239031 | 0.79 | KDM4E (0.54) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL1374020 | 0.79 | TSHR (0.44) | KDM4EMAPTHSD17B10KMT2AHPGD | |
| SCHEMBL2730725 | 0.79 | MAPT (0.44) | KDM4EMAPTNPC1RAB9AHSD17B10 | |
| SCHEMBL1971697 | 0.79 | MAPT (0.44) | KDM4EMAPTHSD17B10ALDH1A1KMT2A | |
| SCHEMBL2729001 | 0.79 | GSK3B (0.43) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL15960083 | 0.79 | MAPT (0.51) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL24523710 | 0.78 | KDM4E (0.53) | KDM4EMAPTNPC1RAB9ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-214973837-U | 3-amino-5-bromothiophene-2-methyl formate preparation feeding device | 安庆睿升医药科技有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-101967141-A | Method for preparing Chk protein kinase antagonist AZD-7762 | SYN THESIS SHANGHAI CO LTD | 2011-02-09 | — | — | CN | claimed |
| WO-2025262243-A1 | THIENO- AND THIAZOLOPYRIMIDINE-2,6-DIONES AND USE THEREOF AS IMMUNOMODULATORS | INVIOS GMBH (AT) | 2025-12-26 | — | — | WO | disclosed |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2025-10-23 | — | — | US | disclosed |
| US-12415813-B2 | Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2025-09-16 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250276979-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-1636238-A1 | HETERORYL-FUSED PYRIMIDINYL COMPOUNDS AS ANTICANCER AGENTS | Chiron Corporation (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1569929-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS | Virochem Pharma Inc. (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-20050065169-A1 | Heteroaryl-fused pyrimidinyl compounds as anticancer agents | CHIRON CORPORATION | 2005-03-24 | — | — | US | disclosed |
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2005-01-13 | — | — | US | disclosed |
| WO-2004111058-A1 | HETERORYL-FUSED PYRIMIDINYL COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004052885-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
| CN-86104822-A | The preparation method of therapeutical agent | — | 1987-12-23 | — | — | CN | disclosed |
| US-4710506-A | Antihypertensive thienopyridines | THE BOOTS COMPANY PLC (GB) | 1987-12-01 | — | — | US | disclosed |
| EP-0209977-A2 | Thienopyridones, processes and intermediates for their preparation and pharmaceutical compositions containing them | The Boots Company PLC (GB) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | KDM4E 1505/4885MAPT 1641/4885NPC1 146/4885 |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | KDM4E 710/4885MAPT 2231/4885NPC1 2317/4885 |
| US-20250276979-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | KDM4E 3744/4885MAPT 2197/4885NPC1 848/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | KDM4E 3744/4885MAPT 2197/4885NPC1 848/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885MAPT 2157/4885NPC1 224/4885 |
| US-20050065169-A1 | Heteroaryl-fused pyrimidinyl compounds as anticancer agents | TYMP, DHFR, PAICS | KDM4E 4270/4885MAPT 4102/4885NPC1 497/4885 |
| US-12415813-B2 | Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor | FARS2, CYP4F11, CYP4B1 | KDM4E 1113/4885MAPT 1936/4885NPC1 3352/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | KDM4E 4059/4885MAPT 2865/4885NPC1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.